What is levacetylleucine? An Overview of Aqneursa for NPC
•
3 min read
In September 2024, the U.S. Food and Drug Administration (FDA) approved Aqneursa, the brand name for the medication levacetylleucine, as a treatment for the neurological manifestations of Niemann-Pick disease type C (NPC). This marked a significant milestone for the rare disease community by providing a new therapeutic option for a debilitating condition.
